- Home
- GCDT vs GLMD Comparison
GCDT vs GLMD Comparison
Compare GCDT & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GCDT | GLMD |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.2M |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GCDT | GLMD |
|---|---|---|
| Price | $0.37 | $3.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 286.2K | 62.8K |
| Earning Date | 05-16-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.41 |
| 52 Week High | $5.32 | $5.45 |
Technical Indicators
Market Signals| Indicator | GCDT | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.06 | 72.35 |
| Support Level | $0.33 | $0.54 |
| Resistance Level | $0.47 | $5.45 |
| Average True Range (ATR) | 0.05 | 0.36 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 3.79 | 70.81 |
Price Performance
Historical ComparisonAbout GCDT Green Circle Decarbonize Technology Limited Ordinary Shares
Green Circle Decarbonize Technology Ltd is a company which provides advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services. As an advocate of decarbonization, the Company designs, develops and provides customized energy saving solutions that bring considerable economic benefits to our clients and reduce carbon emissions for a sustainable future.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.